Cardiatec
At the Heart of Innovation
Cambridge, United Kingdom · Founded 2021
- Headquarters
- Cambridge
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
About
CardiaTec Biosciences is a University of Cambridge spinout applying artificial intelligence to large-scale multi-omic data to discover the next generation of cardiovascular disease drug targets. The company has built a global network of 65 hospitals to develop the largest proprietary human cardiac multiomics dataset, enriched with clinical annotations. Founded in 2021 by Prof. Namshik Han, Raphael Peralta, and Thelma Zablocki, CardiaTec pursues target discovery, drug discovery, and personalised medicine across cardiovascular indications.
Summary
Cardiatec is an Artificial Intelligence company based in Cambridge, United Kingdom, founded in 2021.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company